Linear Energy Transfer (LET), 434
Lipophilic dyes, 155
Liposomes, 107, 160, 198, 374, 415
Logan plot, 300
Lutetium-177, 68, 245
M
Magnetic nanoparticles, 16, 157
Mannose receptor, 236
Marginal metalophillic macrophages. See
(MMMU)
Marginal zone macrophages. See (MZMU)
Memory and trainability, 389
Mesoporous silica nanoparticles. See
(Mesoporous SiNPs)
Metal-based nanomaterials, 194
Micelle encapsulation, 215, 340
Microdosing, 1
Microemulsion method, 191
Microstructure of spleen, 402
Microvesicles, 131, 160
Molecular imaging, 9, 412
Monocyte-derived macrophages, 395
Mononuclear phagocytic system. See
(Reticuloendothelial System)
Multifunctional nanoparticles, 436
Multifunctional radionanomedicine, 222
Multimodal molecular imaging, 423
Multiple linear regression models, 301
Mushroom type PEG configuration, 333
N
Nano carrier systems, 14
Nano-graphene, 193
Nano graphene oxides. See (Nano-GOs)
Nanomedicine, 2
Nanophosphors, 34
Nanoporphyrin, 57
Nanosheets, 34
Non-displaceable Volume of Distribution. See
(VND)
Non-professional Phagocytic Cells, 400
Nuclear mdicine, 1
Number of targeting molecules, 239
O
One-tissue compartment models. See
(Two-compartment Models)
Opsonization, 355
Organic nanoparticles, 106, 196
P
Paracrine effects, 142
Paramagnetic ions coordinated graphene, 92
Paramagnetic nanoparticles-decorated
graphene, 93
Particle shape, 322
Particle size, 314
Pathogen-Associated Molecular Pattern. See
(PAMP)
Pattern Recognition Receptor. See (PRR)
PEGylated biopharmaceutical, 335
PEGylated liposomal Doxorubicin. See (Doxil)
PEGylated liposomes, 376
PEGylated nanomaterials, 397
PEGylated proteins, 372
PEGylation, 8, 213, 315, 333, 372
Pentraxin, 390, 391
Peptides, 416
PET. See (Positron Emission Tomography)
PET/CT, 287
PET/MR, 287
PET Radioisotopes, 221
Pharmacokinetics, 15, 144, 313
Photodynamic therapy, 51, 287
Photoluminescence quenching, 81
Photoluminescence, 81, 90
Photothermal therapy, 90
Phthalocyanine, 51
Physical interaction, 190
Physiologically-based pharmacokinetic model.
See (PBPK)
Poluglycerol-modified lipoplexes, 382
Polyamidoamine. See (PAMAM)
Polycarboxybetaine. See (PCB)
Polyethylene Glycol. See (PEG)
Polyglycerol-derived Lipid, 380
Polyglycerol-modified Lipoplexes, 382
Polyglycolic acid. See (PGA)
Polylactic acid. See (PLA)
Polylactic-co-Glycolic Acid. See (PLGA)
Polymeric micelles, 118, 199
Polymeric nanoparticles, 117, 199
Polyphosphoester-coating. See (PPE-coating)
Porphyrin, 49
Porphyrin radiolabeling, 53
Porphysome, 5, 55
Post-labeling method, 342
Pre-existing anti-PEG antibodies, 377
Pre-labeling method, 342
Pretargeting strategy, 251, 258
Prostate-Specific Membrane Antigen. See
(PSMA)
Protein nanoparticles, 196
Proton beam activation, 221
Q
Quantum dot, 23, 194, 318, 414
Index
445
Lipophilic dyes, 155
Liposomes, 107, 160, 198, 374, 415
Logan plot, 300
Lutetium-177, 68, 245
M
Magnetic nanoparticles, 16, 157
Mannose receptor, 236
Marginal metalophillic macrophages. See
(MMMU)
Marginal zone macrophages. See (MZMU)
Memory and trainability, 389
Mesoporous silica nanoparticles. See
(Mesoporous SiNPs)
Metal-based nanomaterials, 194
Micelle encapsulation, 215, 340
Microdosing, 1
Microemulsion method, 191
Microstructure of spleen, 402
Microvesicles, 131, 160
Molecular imaging, 9, 412
Monocyte-derived macrophages, 395
Mononuclear phagocytic system. See
(Reticuloendothelial System)
Multifunctional nanoparticles, 436
Multifunctional radionanomedicine, 222
Multimodal molecular imaging, 423
Multiple linear regression models, 301
Mushroom type PEG configuration, 333
N
Nano carrier systems, 14
Nano-graphene, 193
Nano graphene oxides. See (Nano-GOs)
Nanomedicine, 2
Nanophosphors, 34
Nanoporphyrin, 57
Nanosheets, 34
Non-displaceable Volume of Distribution. See
(VND)
Non-professional Phagocytic Cells, 400
Nuclear mdicine, 1
Number of targeting molecules, 239
O
One-tissue compartment models. See
(Two-compartment Models)
Opsonization, 355
Organic nanoparticles, 106, 196
P
Paracrine effects, 142
Paramagnetic ions coordinated graphene, 92
Paramagnetic nanoparticles-decorated
graphene, 93
Particle shape, 322
Particle size, 314
Pathogen-Associated Molecular Pattern. See
(PAMP)
Pattern Recognition Receptor. See (PRR)
PEGylated biopharmaceutical, 335
PEGylated liposomal Doxorubicin. See (Doxil)
PEGylated liposomes, 376
PEGylated nanomaterials, 397
PEGylated proteins, 372
PEGylation, 8, 213, 315, 333, 372
Pentraxin, 390, 391
Peptides, 416
PET. See (Positron Emission Tomography)
PET/CT, 287
PET/MR, 287
PET Radioisotopes, 221
Pharmacokinetics, 15, 144, 313
Photodynamic therapy, 51, 287
Photoluminescence quenching, 81
Photoluminescence, 81, 90
Photothermal therapy, 90
Phthalocyanine, 51
Physical interaction, 190
Physiologically-based pharmacokinetic model.
See (PBPK)
Poluglycerol-modified lipoplexes, 382
Polyamidoamine. See (PAMAM)
Polycarboxybetaine. See (PCB)
Polyethylene Glycol. See (PEG)
Polyglycerol-derived Lipid, 380
Polyglycerol-modified Lipoplexes, 382
Polyglycolic acid. See (PGA)
Polylactic acid. See (PLA)
Polylactic-co-Glycolic Acid. See (PLGA)
Polymeric micelles, 118, 199
Polymeric nanoparticles, 117, 199
Polyphosphoester-coating. See (PPE-coating)
Porphyrin, 49
Porphyrin radiolabeling, 53
Porphysome, 5, 55
Post-labeling method, 342
Pre-existing anti-PEG antibodies, 377
Pre-labeling method, 342
Pretargeting strategy, 251, 258
Prostate-Specific Membrane Antigen. See
(PSMA)
Protein nanoparticles, 196
Proton beam activation, 221
Q
Quantum dot, 23, 194, 318, 414
Index
445